Deucravacitinib in the Treatment of Cicatricial Alopecias

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07508488
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Central Centrifugal Cicatricial Alopecia
  • Frontal Fibrosing Alopecia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.

Key Dates

Start date
May 28, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Central Centrifugal Cicatricial Alopecia
    Contains individuals diagnosed with Central Centrifugal Cicatricial Alopecia.
  • Experimental: Frontal Fibrosing Alopecia
    Contains individuals diagnosed with Frontal Fibrosing Alopecia.

Primary Outcome Measure

Changes in IFNγ in CA scalp [ Time Frame: Baseline to Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Giselle Singer
[email protected]
212-241-3288
Benjamin Ungar (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies